Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-aminopyridine N-of-1 crossover trial for KCNA1/KCNA2 gain-of-function epilepsy
ACTRN12624001249549Phase 3Recruiting
- Sponsor
- Austin Health
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalfampridine in epilepsy (2 arms), sponsored by Austin Health. Primary endpoints: Average seizure frequency and Ataxia. Started Dec 2024; status: recruiting.
02
Drugs
dalfampridine
03
Conditions
epilepsy
Beyond the preview
Go deeper on ACTRN12624001249549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001249549.